EPRX logo

EPRX Eupraxia Pharmaceuticals Inc.

NASDAQ · Biotechnology · Healthcare

$6.12
-0.09 (-1.45%)

Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, targeting both critical unmet medical needs and pain management for knee osteoarthritis. This promising candidate is also being developed for veterinary use…

Market Cap: $411.68Mwww.eupraxiapharma.com

Price

No data yet.

Social Signal Score

21
5d
—
30d
20
1 mentions
—
60d
21
4 mentions
—
90d
21
4 mentions
—
news: 4

Analyst Ratings

2 analysts
Buyconsensus
Strong Buy 0Buy 2Hold 0Sell 0Strong Sell 0
Avg price target$16.8+174.5%
Low $11Median $17High $25
Current Consensus

Revenue

$0.00
$0.00
Sep 2019Sep 2026

Analyst Estimates

FY2025
$-0.86
$-1.18–$-0.50
6 analysts
FY2026
$-1.38
$-1.70–$-0.67
8 analysts
FY2027
$-1.52
$-2.01–$-0.45
9 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
James A. Helliwell
Sector
Healthcare
Industry
Biotechnology
Employees
49
Beta
1.50
Country
CA
Piotroski score
1 / 9 (Weak)
Altman Z-score
24.72
www.eupraxiapharma.com